Stocks of anti-obesity drugmakers Eli Lilly , Novo Nordisk , and Amgen have gotten hit as the market frets over what a Robert F. Kennedy Jr.-run Department of Health and Human Ser ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback